Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How are patients transitioned from another basal insulin to Abasaglar® (insulin glargine)?

If transitioning from another basal insulin to Abasaglar, the recommended initial Abasaglar dose is based on the insulin therapy that is being discontinued.


Transitioning from another basal insulin to Abasaglar therapy

Reductions in the Abasaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1,2

Please find a transition table in Transitioning From Another Basal Insulin to Abasaglar Therapy.

Transitioning From Another Basal Insulin to Abasaglar Therapy1,2

If transitioning from…


Then, the recommended initial dose of Abasaglar …




is the same as the Lantus dose.

50 units of Lantus transitions to 50 units of Abasaglar



is 80% of the Toujeo dose.

50 units of Toujeo transitions to 40 units of Abasaglar

twice-daily NPH insulin

once-daily Abasaglar

is 70%-80% of the total daily NPH insulin dosage.

25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 35 units (70% of the NPH insulin total daily dose) or 40 units (80% of the NPH insulin total daily dose) of Abasaglar once daily

an intermediate- or long-acting insulin other than Lantus


may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted.

Abbreviations: Abasaglar  = Abasaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL; Toujeo = Toujeo® (insulin glargine) 300 units/mL.


1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 22 August 2022

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request